You are here
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
PA-19-021: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42 Clinical Trial Not Allowed)Release Date: 10-10-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021
Purpose Digital dentistry uses advanced materials and powerful manufacturing technologies aided by 3D imaging and processing software algorithms to produce dental devices and perform complex dental procedures. This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delive ...STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
PA-19-033 : Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)Release Date: 10-24-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021
Background The human genome has revealed a great deal about the human proteome, though significant portions remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be discovered in the "Druggable Genome" (DG), which can be defined as a subset of the ~20,000 ...STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
RFA-DA-19-020 : HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R41/R42- Clinical Trial Optional)Release Date: 12-10-2018Open Date: 12-10-2018 Due Dates: Multiple Close Date: 09-08-2021
The National Center for Advancing Translational Sciences (NCATS) will not accept primary assignment to applications proposing clinical trial(s) under this funding announcement. Please direct any questions to the NCATS scientific contact. Purpose More than 2 million individuals in the United States have an opioid use disorder (OUD), most starting with opioid analgesics prescribed to them or procu ...STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
PA-19-075 : Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42 Clinical Trial Not Allowed)Release Date: 11-26-2018Open Date: 03-05-2019 Due Dates: Multiple Close Date: 01-05-2022
Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited ...STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
PAS-19-317 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)Release Date: 07-18-2019Open Date: 12-05-2019 Due Dates: Multiple Close Date: 09-05-2022
Recent recommendations and milestones for AD/ADRD research from the National Alzheimer’s Project Act, the 2015 Alzheimer’s Disease Research Summit, the 2018 Alzheimer’s Disease Research Summit, and the 2019 Alzheimer’s Disease and Related Dementias Research Summit present a wide range of research and development proposals which, if pursued, can reduce the human burden and healthcare costs ...STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health